Earnings Flash (TXG) 10x Genomics Posts Q2 Per Share Loss $0.14, vs. FactSet Est of $0.24 Loss
10x Genomics (TXG) reported Q2 EPS loss of $0.14, narrower than FactSet’s $0.24 loss estimate, and said Q2 revenue fell. The company also guided 2026 revenue to $610M-$630M versus FactSet’s $613.7M estimate.
How this was made
The 30-second read
Why it matters
Traders can use the EPS miss and the 2026 revenue range to update near-term expectations and position for the next earnings revisions cycle.
Market read
Company-specific earnings and forward revenue guidance provide a direct catalyst for TXG’s next-session trading and estimate revisions.
What to watch
The article does not include cash flow, gross margin, or segment drivers, which are often the real determinants of whether the guidance is conservative or achievable.
Background
The piece is an earnings flash summarizing TXG’s Q2 EPS result and its 2026 revenue outlook.
Ticker impact
10x Genomics (TXG) reported Q2 EPS loss of $0.14 versus FactSet’s $0.24 loss and issued a 2026 revenue range of $610M-$630M.
Likely choppy trading as investors weigh the EPS miss against roughly in-line 2026 revenue guidance.
The article provides both the quarterly EPS result and the forward revenue range, which typically drives immediate estimate revisions and sentiment.
Market effects
Biotech/life-science tools sentiment may be influenced if TXG’s guidance is read as demand stability or softness for genomics workflows.
Limited, primarily US small/mid-cap growth sentiment tied to earnings/guidance.
Low, as the disclosed facts are company-specific rather than macro or cross-border policy.
Counterpoint
Investors may focus on the 2026 revenue range being close to the $613.7M FactSet estimate, treating the EPS miss as timing or non-recurring cost noise.
Key entities
- company10x Genomics
Reported Q2 EPS loss of $0.14 vs FactSet’s $0.24 loss and guided 2026 revenue to $610M-$630M.
